Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Phenol derivatives constitute a family of neuroactive compounds. The aim of our study was to identify structural features that determine their modulatory effects at glycine receptors. We investigated the effects of four methylated phenol derivatives and two halogenated analogues on chloride inward currents via rat α 1 and α 1 β glycine receptors, heterologously expressed in HEK 293. All compounds potentiated the effect of a submaximal glycine concentration in both α 1 homomeric and α 1 β glycine receptors. While the degree of maximum potentiation of the glycine 10 μM effect in α 1 β receptors was not different between the compounds, the halogenated compounds achieved half-maximum potentiating effects in the low μM range - at more than 20-fold lower concentrations compared with their nonhalogenated analogues (P < 0.0001). The coactivating effect was over-ridden by inhibitory effects at concentrations > 300 μM in the halogenated compounds. Neither the number nor the position of the methyl groups significantly affected the EC 50 for coactivation. Only the bimethylated compounds 2,6 and 3,5 dimethylphenol (at concentrations > 1000 μM) directly activated both α 1 and α 1 β receptors up to 30% of the maximum response evoked by 1000 μM glycine. These results show that halogenation in the para position is a crucial structural feature for the potency of a phenolic compound to positively modulate glycine receptor function, while direct activation is only seen with high concentrations of compounds that carry at least two methyl groups. The presence of the β subunit is not required for both effects. © 2005 Nature Publishing Group All rights reserved.

Original publication

DOI

10.1038/sj.bjp.0706254

Type

Journal article

Journal

British Journal of Pharmacology

Publication Date

01/08/2005

Volume

145

Pages

916 - 925